metabolic diseases
MiNA’s gene-activating tech wins an AstraZeneca alliance
Phil Taylor
AstraZeneca, metabolic diseases, MiNA Therapeutics, RNA-based drugs
0 Comment
Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome
Phil Taylor
Diabetes, metabolic diseases, Novo Nordisk, Ozempic, semaglutide
0 Comment
News/ News/ R&D/ Top stories
Vertex looks beyond cystic fibrosis with $950m Semma buy
Phil Taylor
M&A, metabolic diseases, stem cell therapy, type 1 diabetes, Vertex
0 Comment
Pfizer, Novo invest in Swedish patient stratification startup
Marco Ricci
digital health, metabolic diseases, Novo Nordisk, Pfizer, startup
0 Comment
Funds will go towards development of AMRA’s body composition profiling tool AMRA Profiler.